InvestorsHub Logo
Followers 137
Posts 22805
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Thursday, 09/08/2022 4:14:36 PM

Thursday, September 08, 2022 4:14:36 PM

Post# of 660
On September 8, 2022, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing the enrollment of the first patient in the Company’s ADVANCE-2 (Addressing Dementia via Agitation-Centered Evaluation-2) Phase 3 trial of AXS-05 for the treatment of agitation associated with Alzheimer's disease.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001579428/000095017022018238/axsm-20220908.htm

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News